<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036174</url>
  </required_header>
  <id_info>
    <org_study_id>415-5.13.04.2021-1</org_study_id>
    <nct_id>NCT05036174</nct_id>
  </id_info>
  <brief_title>Diphenhydramine Ointment for Knee Osteoarthritis</brief_title>
  <official_title>Diphenhydramine 5% Ointment for Pain in Knee Osteoarthritis: a Randomised Double-blind Placebo-controlled Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate whether recruitment rates are adequate to power&#xD;
      a future RCT. The secondary aims are to obtain preliminary information about safety and&#xD;
      efficacy of topical diphenhydramine 5% ointment in patients with knee OA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rates</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Ability to recruit 8 patients per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refusal rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of eligible patients who refuse to participate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of patients adhering to 80% of allocated treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for Pain</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>The Visual Analogue Scale for Pain varies from 0 to 10 cm. Higher values represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Pain</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>KOOS Pain consists of 9 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Symptoms</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>KOOS Symptoms consists of 7 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Activities of daily living (ADL)</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>KOOS ADL consists of 17 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale of function in sports and recreation (Sport/Rec)</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>KOOS Sport/Rec consists of 5 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale of quality of life (QOL)</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>KOOS QOL subscale of quality of life consists of 4 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for patient global assessment</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>The Visual Analogue Scale for patient global assessment varies from 0 to 10 cm. Higher values represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of treatment by patient</measure>
    <time_frame>Baseline to week 1</time_frame>
    <description>Global evaluation of treatment by patient on 5 point Likert scale. The Global Evaluation of treatment varies from 0 to 5. Higher values represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving minimal clinically important improvement (MCII) of visual analogue scale (VAS) pain</measure>
    <time_frame>Week 1</time_frame>
    <description>Percentage of patients achieving MCII of VAS pain. The cut-off for MCII changes will be 15 of 100 for absolute improvement and 20% for relative improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving minimal clinically important improvement (MCII) of visual analogue scale (VAS) patient's global assessment</measure>
    <time_frame>Week 1</time_frame>
    <description>Percentage of patients achieving MCII of VAS patient's global assessment The cut-offs for MCII changes will be 15 of 100 for absolute improvement and 20% for relative improvement for patient's global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving minimal clinically important improvement (MCII) of Knee injury and Osteoarthritis Outcome Score (KOOS) function of daily living</measure>
    <time_frame>Week 1</time_frame>
    <description>Percentage of patients achieving MCII of Knee injury and Osteoarthritis Outcome Score (KOOS) subscale of function of daily living.&#xD;
The cut-offs for MCII changes will be 8 of 100 for absolute improvement for KOOS function in daily living subscale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>Any adverse event occurred during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical 5% diphenhydramine ointment applied at knee joint at a dose of 2 g three times a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (placebo) ointment applied at knee joint at a dose of 2 g three times a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine 5%</intervention_name>
    <description>Diphenhydramine 5% ointment</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to diphenhydramine 5% ointment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ACR clinical criteria of knee OA&#xD;
&#xD;
          2. Radiographic knee OA (Kellgren-Lawrence grade &gt;1)&#xD;
&#xD;
          3. Age â‰¥ 50 years&#xD;
&#xD;
          4. VAS pain &gt;= 40/100 mm at baseline&#xD;
&#xD;
          5. Non-use of NSAIDs one week before the baseline&#xD;
&#xD;
          6. Symptoms present on most days for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any form of inflammatory arthritis&#xD;
&#xD;
          2. Use of another topical product at the application site&#xD;
&#xD;
          3. Treatment with intraarticular hyaluronic acid within 6 months&#xD;
&#xD;
          4. Treatment with intraarticular glucocorticoid within 2 months&#xD;
&#xD;
          5. Knee injury/surgery or diagnostic arthroscopy within 3 months&#xD;
&#xD;
          6. Allergic reaction to diphenhydramine or any component of the formulation&#xD;
&#xD;
          7. Participant has clinical signs and symptoms suggestive of COVID-19, eg, fever, dry&#xD;
             cough, dyspnea, sore throat, fatigue or confirmed infection by appropriate laboratory&#xD;
             test within the last 4 weeks prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivan Shirinsky, MD, Doctor of Science</last_name>
    <phone>+73832282547</phone>
    <email>ivan.shirinsky@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valery Shirinsky, Professor, MD</last_name>
    <phone>+73832282547</phone>
    <email>valery.shirinsky@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory of Clinical Immunopharmacology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</investigator_affiliation>
    <investigator_full_name>Ivan Shirinsky, MD, PhD</investigator_full_name>
    <investigator_title>Head of the laboratory of immunopharmacology</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>pain</keyword>
  <keyword>antihistamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

